Article Details

Indalo Therapeutics Initiates Dosing in IPF Patients with Lead Antifibrotic Drug Candidate IDL-2965

Retrieved on: 2019-10-20 20:00:00

Tags for this article:

Click the tags to see associated articles and topics

Indalo Therapeutics Initiates Dosing in IPF Patients with Lead Antifibrotic Drug Candidate IDL-2965. View article details on hiswai:

Excerpt

<div><b>Atlas Venture</b> and F-Prime Capital co-led the company's Series A financing in 2017. The company has also received funding from BioGenerator, MTC, ...</div>

Article found on:

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up